Log in
Enquire now
‌

US Patent 12090147 Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Patent 12090147 was granted and assigned to Celgene on September, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Celgene
Celgene
0
Current Assignee
Celgene
Celgene
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
120901470
Patent Inventor Names
Daniel W. Pierce0
Tonia Buchholz0
Michael Pourdehnad0
Tsun-Wen Yao0
Jinhong Fan0
Date of Patent
September 17, 2024
0
Patent Application Number
170893590
Date Filed
November 4, 2020
0
Patent Citations
‌
US Patent 7605238 Human CTLA-4 antibodies and their uses
0
‌
US Patent 7943743 Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
0
‌
US Patent 8008449 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
0
‌
US Patent 8168757 PD-1 binding proteins
0
‌
US Patent 8217149 Anti-PD-L1 antibodies, compositions and articles of manufacture
0
‌
US Patent 9499514 Antiproliferative compounds and methods of use thereof
0
‌
US Patent 9808451 Antiproliferative compounds and methods of use thereof
0
‌
US Patent 9968596 Antiproliferative compounds and methods of use thereof
0
...
Patent Primary Examiner
‌
Rei Tsang Shiao
0
CPC Code
‌
A61K 31/454
0
Patent abstract

Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 12090147 Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.